Biologic readiness: Improving tuberculosis screening in an adult allergy and immunology clinic Authors: Kimberly Lovie Murdaugh, Alexis Flen, Raphaela Martina C Pineda, Shirley Gomez, Kyara C Ramdhanie Lalla, Sharon Glick, Mary F Lee-Wong Published: 2026 ABSTRACT AbstractBackgroundIn outpatient allergy settings serving historically underserved populations, compliance with Mycobacterium tuberculosis (TB) screening and documentation remains challenging.ObjectiveWe evaluated TB screening compliance among adult allergy patients receiving biologic therapy to identify workflow gaps that contribute to incomplete screening.MethodsWe conducted a quality improvement project within the Division of Adult Allergy and Immunology at Maimonides Health, an urban academic medical center in Brooklyn, New York, serving a diverse patient population with significant social and medical complexity. Demographic and clinical data were collected from patients receiving biologic therapy between 2023 and 2025. TB screening completion and documentation rates were analyzed using descriptive statistics. A FOCUS-PDCA (find, organize, clarify, understand, select; plan, do, check, act) framework was applied to identify sources of process variation and to develop standardized workflow interventions.ResultsAmong 141 patients receiving biologic therapy, only 46.81% had documented TB screening results, leaving 53.19% without evidence of completed testing. The mean patient age was 43 years, with most patients aged between 30-44 and 45-59 years. Omalizumab (61%) and dupilumab (38%) were the most frequently prescribed biologics. Major contributors to incomplete TB screening included inconsistent documentation, lack of automated electronic medical record alerts, variable workflows across clinical sites, and patient noncompletion of laboratory testing.ConclusionImplementing standardized TB screening workflows, improving laboratory follow-up processes, and enhancing patient education may significantly improve compliance. Targeting frequently utilized biologic therapies offers an efficient strategy for system-wide improvement.Key words: Tuberculosis screening, latent tuberculosis infection, allergy, patient safety, quality improvement Biologic therapies have transformed the management of allergic and immunologic diseases by reducing inflammation, improving symptom control, and enhancing quality of life. Agents such as omalizumab (Xolair), dupilumab (Dupixent), and tezepelumab (Tezspire) are increasingly used in allergic and immunologic disease, with indication-specific use across asthma, atopic dermatitis, and chronic rhinosinusitis.1, 2, 3, 4 However, these therapies also alter immune function and may impair the body’s ability to contain latent infections, including Mycobacterium tuberculosis (TB).5, 6, 7, 8 Screening for latent TB infection using IFN-γ release assays, such as the QuantiFERON Gold test, is an advised safety measure before initiating biologic therapy, especially in high-risk populations.9 However, adherence to TB screening protocols in outpatient specialty clinics can be inconsistent.9, 10, 11, 12, 13 Delays in laboratory completion, fragmented documentation, and workflow variability can all contribute to incomplete screening and potential patient harm.9 This quality improvement project aimed to evaluate TB screening compliance in an adult allergy and immunology clinic and to identify system-level opportunities for improving biologic readiness and patient safety. Methods This phase 1 (diagnostic) quality improvement initiative was conducted within the Division of Adult Allergy and Immunology across two outpatient clinical sites between 2023 and 2025 and included patients receiving or being evaluated for biologic therapy. Data were extracted from clinical records and tracked in a secure spreadsheet with all identifiers replaced by patient numbers to maintain compliance with the Health Insurance Portability and Accountability Act. Variables collected included age, sex, biologic medication, dosage, indication, initial appointment date, and TB QuantiFERON Gold test status. The FOCUS-PDCA (find, organize, clarify, understand, select; plan, do, check, act) framework was used to evaluate existing workflows, identify sources of process variation, and design targeted interventions.14 Descriptive statistics were used to characterize the patient population and quantify TB screening completion rates. Workflow barriers were identified through chart review and process mapping. As part of baseline safety assessment, patients evaluated for biologic therapy are required to undergo TB screening using a QuantiFERON assay before treatment initiation. In addition, adult allergy and immunology care providers routinely verify TB screening status for patients transitioning from pediatric care, even when biologic therapy has already been initiated. In the existing workflow, biologic initiation depended on whether TB testing was ordered and completed, resulting in two primary pathways: test completion with documented results versus pending or incomplete testing requiring follow-up. When TB testing was completed, results were documented in the electronic medical record, biologic therapy was authorized, and prior authorization processes were initiated. In contrast, when TB results were not available at the time of biologic decision-making, treatment initiation could be delayed or could proceed without documented screening, depending on clinical circumstances and authorization status. This variability in workflow contributed to inconsistent documentation and follow-up of TB screening before biologic therapy initiation. Results Maimonides Health serves one of the most diverse and socioeconomically complex patient populations in New York City.15,16 The hospital’s primary service area includes a racially and ethnically heterogeneous population, with approximately 41% identifying as White, 18% Hispanic/Latino, 17% Black/African American, 15% Asian/Pacific Islander, and 9% other or unknown. Approximately 43% to 44% of individuals in the service area are foreign born, with substantial representation from regions with higher global TB prevalence, including South and Southeast Asia, the Caribbean, Eastern Europe, Latin America, and East Asia. The patient population is predominantly publicly insured, with over 80% of admitted patients and approximately 74% of outpatients covered by Medicare or Medicaid; an estimated 13% of patients are uninsured. The service area spans neighborhoods with elevated poverty rates—reaching up to 27% in Borough Park and 24% in Coney Island—exceeding the New York City average of approximately 18% to 19%. Educational attainment is also lower than citywide averages, with up to 38% of residents in some neighborhoods having less than a high school education. Collectively, these structural and demographic characteristics underscore the importance of reliable TB screening and documentation workflows in this outpatient specialty care setting. These demographic and socioeconomic characteristics are summarized in Table I.15,16 Table IDemographic and socioeconomic characteristics of Maimonides Health service areaCharacteristicEstimateRace/ethnicity White∼41% Hispanic/Latino∼18% Black/African American∼17% Asian/Pacific Islander∼15% Other/unknown∼9%Immigration and language Foreign-born population∼43-44% Limited English proficiency∼30%Insurance status Medicare/Medicaid (inpatient)>80% Medicare/Medicaid (outpatient)∼74% Uninsured∼13%Poverty rate Borough Park neighborhoodUp to 27% Coney Island neighborhoodUp to 24% NYC average∼18-19%Education Less than high school educationUp to 38%TB context Regions with higher global TB prevalence represented in service areaSouth/Southeast Asia, Caribbean, Eastern Europe, Latin America, East AsiaData from Maimonides Health community health needs assessment and community service plans for 2019 and 2022-24.15,16 Demographic and socioeconomic characteristics of Maimonides Health service area Data from Maimonides Health community health needs assessment and community service plans for 2019 and 2022-24.15,16 A total of 141 patients receiving biologic therapy were identified (mean age, 43 years; range, 19-84 years), with most patients in the 30-44 and 45-59 age groups. The mildly right-skewed age distribution (skewness = 0.30) underscores the need for standardized TB screening across a diverse adult population. Omalizumab was the most commonly prescribed biologic (61.0%), followed by dupilumab (38.3%), with minimal prescription of tezepelumab (0.7%). No patients receiving anti-TNF therapy were identified during the study period. Focusing improvement efforts on omalizumab and dupilumab therefore offered the greatest potential impact. Only 46.8% of patients had documented TB screening results, leaving 53.2% without evidence of completed testing. Age distributions and prescribed biologics are summarized in Table II. Table IIDemographic characteristics and biologic therapy distribution among 141 adult allergy and immunology patients receiving biologic treatmentCharacteristicValueAge (years) Mean (SD)43.4 (14.3) Median [min, max]43.0 [19-84]Age group 19-29 years27 (19.1%) 30-44 years48 (34%) 45-59 years46 (32.6%) 60-74 years18 (12.8%) 75-84 years2 (1.4%)Sex Female82 (58.2%) Male59 (41.8%)Biologic therapy Omalizumab86 (61%) Dupilumab54 (38.3%) Tezepelumab1 (0.7%) Demographic characteristics and biologic therapy distribution among 141 adult allergy and immunology patients receiving biologic treatment To identify contributors to incomplete TB screening documentation, a root cause analysis was performed using a fishbone (Ishikawa) diagram (Fig 1). Contributing factors were categorized across equipment/technology, process, people, materials/environment, and management domains. This analysis identified multiple system-level contributors to missing TB QuantiFERON results, including the absence of automated electronic medical record alerts, lack of a standardized prebiologic checklist, inconsistent ordering practices across providers, and variable documentation locations within the electronic medical record. Additionally, the absence of automated follow-up for overdue laboratory testing, patient noncompletion of laboratory appointments, high patient volume, and limited time for patient education further contributed to incomplete screening. Fishbone (Ishikawa) diagram depicting identified contributors to incomplete TB QuantiFERON screening documentation among patients receiving biologic therapy, categorized by equipment/technology, process, people, materials/environment, and management domains. Four patients (2.8% of the cohort) were found to have positive QuantiFERON results consistent with latent TB infection (LTBI). In all such cases, TB screening had been completed before biologic initiation, LTBI was diagnosed months after biologic initiation during routine follow-up. These cases were reported to the New York City Department of Health and Mental Hygiene, evaluated by pulmonary and/or infectious diseases specialists, and treated appropriately for LTBI in accordance with institutional and public health guidelines.17,18 Biologic therapy was initiated after completion of LTBI treatment, typically within 6 to 9 months. No cases of active TB were identified in this cohort. Discussion This quality improvement study identified a substantial gap in TB screening documentation among adult allergy and immunology patients receiving biologic therapy at Maimonides Health, an urban academic medical center serving a diverse and historically underserved population in Brooklyn, New York. More than half of patients lacked documented TB QuantiFERON results, representing a modifiable patient safety risk with important clinical, public health, and health system implications. Biologic therapies have become foundational in the management of allergic and immunologic disease; however, their immunomodulatory effects can impair host immune surveillance and increase the risk of reactivation of LTBI.6, 7, 8, 9, 10,15 Reactivation of LTBI in this setting is associated with significant morbidity, prolonged multidrug treatment courses, and potential treatment interruptions or discontinuation of biologic therapy. Patients may experience delays in care, adverse effects from antituberculous medications, and increased risk of complications, particularly in those with underlying comorbidities.9, 10, 11, 12,19 Beyond individual patient outcomes, undiagnosed LTBI progressing to active TB has critical public health consequences. Active TB is a communicable disease requiring airborne isolation, extensive contact tracing, and coordination with local and state public health authorities.17,18,20 A single case may necessitate evaluation of numerous close contacts, including household members, coworkers, and health care personnel, placing a substantial burden on public health infrastructure.18,20,21 In outpatient specialty clinics with high patient volume, delayed identification of TB also increases the risk of exposure in shared clinical environments, including exposure of health care personnel.22 As such, TB screening before biologic initiation serves not only as an individual safety measure but also as an essential public health intervention.17 From a health systems perspective, the cost differential between TB screening and biologic therapy further emphasizes the importance of screening compliance. TB QuantiFERON testing represents a relatively low-cost, one-time intervention, whereas biologic therapies such as omalizumab and dupilumab are associated with annual costs in the tens of thousands of dollars per patient.23, 24, 25, 26, 27 Failure to complete TB screening before initiating biologics may lead to costly downstream consequences, including hospitalizations for active TB, prolonged antimicrobial therapy, public health investigations, and treatment interruptions.15 Ensuring completion and documentation of TB screening therefore represents a cost-effective strategy that protects both patient safety and the substantial financial investment associated with biologic treatment.28 Although TB screening is not uniformly mandated for all biologic therapies used in allergic and immunologic disease, screening was pursued in this population due to clinical concern arising from real-world patient presentations. Although the absolute risk of TB reactivation may be low for certain biologic therapies, the population served by this clinic includes a high prevalence of TB risk factors, such that missed or undocumented screening—even if infrequent—may carry disproportionate consequences. This initiative does not assert causal associations between non-TNF biologics and TB reactivation or challenge existing guidelines, but evaluates the reliability of screening workflows in this context. Our findings highlight the vulnerability of complex outpatient workflows when safety processes are not standardized. The predominance of high-volume biologics such as omalizumab and dupilumab in this cohort suggests that targeted improvements focused on these therapies may yield the greatest impact. Addressing system-level barriers, rather than attributing incomplete screening solely to patient noncompliance, is essential. Identified contributors included inconsistent documentation, lack of automated electronic medical record alerts, variable workflows across clinical sites, and gaps in laboratory follow-up. Standardized workflows, automated reminders, centralized documentation, and structured follow-up processes may reduce variability, improve compliance, and enhance biologic readiness across care settings. In conclusion, more than half of patients receiving biologic therapy in this adult allergy and immunology clinic lacked documented TB screening, exposing patients and health systems to preventable clinical, public health, and financial risks. Implementing standardized TB screening workflows and improving laboratory tracking and follow-up represent low-cost, high-impact interventions that can significantly enhance patient safety. Ongoing monitoring across clinical sites will be essential to sustain improvements and ensure safe, effective use of biologic therapies in an expanding patient population. This project represents the diagnostic phase of a larger quality improvement initiative; no formal intervention was implemented during the study period. Planned next steps include development of a standardized prebiologic checklist, incorporation of electronic medical record–based ordering prompts and reminders, and establishment of a centralized process for tracking TB screening completion and results. Subsequent QI cycles will assess the impact of these interventions on screening rates, timeliness, and documentation reliability. Key messages •Incomplete TB screening before biologic therapy poses preventable safety, public health, and cost risks. Incomplete TB screening before biologic therapy poses preventable safety, public health, and cost risks. •Standardized workflows and electronic medical record–based tracking can markedly improve biologic readiness and patient safety. Standardized workflows and electronic medical record–based tracking can markedly improve biologic readiness and patient safety. Disclosure statement Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. References